A Novel Biology Platform
ERX Pharmaceuticals was founded in 2014 based on discoveries by Dr. Umut Ozcan, an Associate Professor at Boston Children’s Hospital and Harvard Medical School, whose lab researches the mechanisms that lead to the development of obesity and obesity-associated metabolic diseases. By using a novel systems-biology approach, Dr. Ozcan identified ERX-1000, a first-in-class leptin sensitizer.
ERX-1000 showed an unprecedented 45% reduction in body weight in preclinical studies in diet-induced severely obese mice
ERX-1000 recently completed a first-in-human Phase 1, double-blind, placebo-controlled, single and multiple oral dose study in healthy obese and non-obese subjects. ERX holds worldwide commercialization rights to ERX-1000 and a family of compounds from Boston Children’s Hospital pursuant to an exclusive license.
- National Center for Health Statistics
- Wang YC, et al. Lancet. 2011;378:815-25.
- US Department of Health and Human Services National Heart, Lung, and Blood Institute. Managing Overweight and Obesity in Adults. 2013.